

Stephen R Bloom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919303/publications.pdf>

Version: 2024-02-01

28
papers

932
citations

623734

14
h-index

526287

27
g-index

38
all docs

38
docs citations

38
times ranked

1089
citing authors

#	ARTICLE	IF	CITATIONS
1	Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. <i>Diabetes</i> , 2013, 62, 1131-1138.	0.6	182
2	Targeting GLP-1 receptor trafficking to improve agonist efficacy. <i>Nature Communications</i> , 2018, 9, 1602.	12.8	162
3	Control of insulin secretion by GLP-1. <i>Peptides</i> , 2018, 100, 75-84.	2.4	69
4	Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. <i>PLoS Biology</i> , 2019, 17, e3000097.	5.6	61
5	Allosteric Optical Control of a Class B G-protein-Coupled Receptor. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 5865-5868.	13.8	45
6	A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β -Cells. <i>Diabetes</i> , 2018, 67, 385-399.	0.6	41
7	Genetic and biased agonist-mediated reductions in β -arrestin recruitment prolong cAMP signaling at glucagon family receptors. <i>Journal of Biological Chemistry</i> , 2021, 296, 100133.	3.4	41
8	Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide. <i>British Journal of Pharmacology</i> , 2020, 177, 3905-3923.	5.4	36
9	RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. <i>Endocrinology</i> , 2017, 158, 2680-2693.	2.8	33
10	Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. <i>Molecular Metabolism</i> , 2020, 37, 100991.	6.5	32
11	The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 345-360.	4.9	32
12	Potent Prearranged Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor. <i>ChemistryOpen</i> , 2017, 6, 501-505.	1.9	31
13	Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8404.	4.1	28
14	Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. <i>Molecular Metabolism</i> , 2021, 53, 101296.	6.5	23
15	Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases. <i>Endocrinology</i> , 2017, 158, 1755-1765.	2.8	16
16	The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e767-e782.	3.6	16
17	Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking. <i>Molecular Pharmacology</i> , 2021, 100, 319-334.	2.3	13
18	A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. <i>BMJ Open</i> , 2017, 7, e018598.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Allosterische optische Steuerung eines Klasseâ€Bâ€Câ€B-Proteinâ€Bgekoppelten Rezeptors. Angewandte Chemie, 2016, 128, 5961-5965.	2.0	10
20	Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. Expert Opinion on Drug Discovery, 2019, 14, 1151-1159.	5.0	9
21	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. Biochemical Pharmacology, 2021, 190, 114656.	4.4	8
22	Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. Molecular Metabolism, 2021, 51, 101242.	6.5	7
23	Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3â€B6 and its analogues in vivo. Lancet, The, 2015, 385, S28.	13.7	4
24	Hepatocyte cholesterol content modulates glucagon receptor signalling. Molecular Metabolism, 2022, 63, 101530.	6.5	4
25	Learning curve of vessel cannulation in rats using cumulative sum analysis. Journal of Surgical Research, 2015, 193, 69-76.	1.6	3
26	Live demo: Platform for closed loop neuromodulation based on dual mode biosignals. , 2017, , .		2
27	Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. Journal of Investigative Surgery, 2017, 30, 162-169.	1.3	1
28	Effects of Elevating Colonic Propionate on Liver Fat Content in Adults with Nonâ€BAlcoholic Fatty Liver Disease. FASEB Journal, 2015, 29, 385.2.	0.5	1